Evidence map›Paper›PMID 38781964›Full record

ArticleCell reports. Medicine2024

Vaccination with nanoparticles displaying gH/gL from Epstein-Barr virus elicits limited cross-protection against rhesus lymphocryptovirus.

Kristina R Edwards, Karina Schmidt, Leah J Homad, Gargi M Kher, Guoyue Xu, Kristen A Rodrigues, Elana Ben-Akiva, Joe Abbott, Martin Prlic, Evan W Newell and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kristina R EdwardsVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA.
Karina SchmidtVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Leah J HomadVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Gargi M KherVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Guoyue XuVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA.
Kristen A RodriguesKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA.
Elana Ben-AkivaKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA; Departments of Biological Engineering and Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Joe AbbottVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Martin PrlicVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA; Department of Immunology, University of Washington, Seattle, WA, USA.
Evan W NewellVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA.
Stephen C De RosaVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Darrell J IrvineKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA, USA; Harvard-MIT Health Sciences and Technology Program, Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
Marie PanceraVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Andrew T McGuireVaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. Electronic address: amcguire@fredhutch.org.

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
Diseases of Public Health Importance Training GrantT32AI007509 · NIAID · UNIVERSITY OF WASHINGTON · PI LUND, JENNIFER M · 1997 to 2024
$6.3M
Vaccine design to augment protective efficacy of antibodies against the EBV gH/gL glycoprotein complexR01AI147846 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Andrew McGuire · 2019 to 2026
$4.8M
The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinomaR01CA264646 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI NEWELL, EVAN · 2021 to 2025
$3.0M
Rational Vaccine Design to prevent HIV-Associated LymphomaR01CA285227 · NCI · FRED HUTCHINSON CANCER CENTER · PI Andrew McGuire · 2024 to 2026
$2.0M
NCI NIH HHS R01 CA264646NCI NIH HHS R01 CA285227NIAID NIH HHS R01 AI147846NIAID NIH HHS T32 AI007509NIH HHS P51 OD010425
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) is associated with infectious mononucleosis, cancer, and multiple sclerosis. A vaccine that prevents infection and/or EBV-associated morbidity is an unmet need. The viral gH/gL glycoprotein complex is essential for infectivity, making it an attractive vaccine target. Here, we evaluate the immunogenicity of a gH/gL nanoparticle vaccine adjuvanted with the Sigma Adjuvant System (SAS) or a saponin/monophosphoryl lipid A nanoparticle (SMNP) in rhesus macaques. Formulation with SMNP elicits higher titers of neutralizing antibodies and more vaccine-specific CD4

Indexed as

Antibodies, NeutralizingHerpesvirus 4, HumanLymphocryptovirusMacaca mulattaNanoparticlesVaccinationAdjuvants, ImmunologicAnimalsAntibodies, ViralEpstein-Barr Virus InfectionsHerpesviridae InfectionsHumansViral VaccinesAdjuvants, ImmunologicAntibodies, NeutralizingAntibodies, ViralViral Vaccinesadjuvantschallenge studiesEpstein-Barr virusnanoparticlesneutralizing antibodiesrhesus lymphocryptovirusvaccines

Identifiers

PMID38781964
PMCPMC11228584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.